Table 2 FDA-approved ALK TKIs
From: Emerging therapeutic agents for advanced non-small cell lung cancer
Drug | Month/year | Indication | Comments |
|---|---|---|---|
Crizotinib | August/2011 | Metastatic ALK+ NSCLC | First generation |
Ceritinib | April/2014 | Metastatic ALK+ NSCLC | Second generation |
Alectinib | December/2015 | Metastatic ALK+ NSCLC who have progressed on or are intolerant to crizotinib | Second generation |
November/2017 | Metastatic ALK+ NSCLC | ||
Brigatinib | April/2017 | Metastatic ALK+ NSCLC who have progressed on or are intolerant to crizotinib | Second generation |
Lorlatinib | November/2018 | Metastatic ALK+ NSCLC who has progressed on alectinib or ceritinib, or crizotinib and at least one other ALK inhibitor | Third generation |